Blocking of mononuclear cell activation by lonazolac.
The immunological effect of lonazolac on mononuclear cell activation has been investigated using the indirect Leukocyte Adherence Inhibition Test in Arthritis. Under these conditions, the mononuclear cell response to a synovial stimulus can be abolished by very low concentrations of lonazolac, a new nonsteroidal antiinflammatory drug. This blockade can be completely released by the addition of prostaglandin E2. Lonazolac appears therefore as an agent able in addition to modulate the immune response.